2015 Molecular Pharmacology Gordon Research Conference/Gordon Research Seminar

 描述(由申请人提供)：本提案请求部分支持2015年联合戈登研究研讨会(GRS)和2015年分子药理学戈登研究会议(GRC)，分别于2015年1月31日至2月1日和2月1日至6日在加利福尼亚州文图拉举行。这次会议的广泛和长期目标是通过整合基础研究和翻译研究，让与会者了解和参与有关药物作用的分子基础的最新发现和重大问题的讨论。主要的重点是强调在细胞系统和动物模型中药物受体的分子机制和病理生理学方面的最新进展。这些会议的具体目标将是在GRS和GRC分别召集50名和~200名与会者；预计将有9人担任讨论领导者，~38人担任演讲者。的关注点 这个GRS和GRC将基于G蛋白偶联受体(GPCRs)--它们的结构、作用机制、调节以及在各种生理和病理生理状态中的作用，突出了在成瘾中的作用。为期两天的GRS项目，面向学生和博士后研究员，将在GRC之前，并将有一个主题演讲，两个口头会议和两个海报会议。GRC的主要计划将有一个主旨演讲会议开幕，7个科学会议和一个闭幕全体会议将集中在上述主题。除了口头陈述外，还将提供充分的海报陈述机会；鼓励每一位非演讲者展示一张海报。这一应用的意义在于，GRS/GRC为广泛的科学家提供了一个独特的机会，以协同和加快对基础和临床科学具有重大意义的主题的研究步伐。这一申请和会议与健康相关的是，GPCRs是人类基因组中最大的受体家族，也是目前可用药物最广泛使用的靶标。此外，GPCRs在包括药物滥用和神经精神疾病在内的大量临床疾病的发病机制和治疗方面发挥着关键作用。这次会议的预期结果将是在那些和其他环境中GPCRs和GPCR信号已被认为对生理学和病理生理学重要的环境中取得的进展。

 DESCRIPTION (provided by applicant): This proposal requests partial support for the joint 2015 Gordon Research Seminar (GRS) and the 2015 Molecular Pharmacology Gordon Research Conference (GRC), to be held in Ventura, CA January 31-February 1 and February1-6, 2015, respectively. The broad and long-term goals of this conference are to inform and engage participants in discussions of recent discoveries and major questions regarding the molecular basis of drug action by integrating basic and translational research. The principal focus is on highlighting recent advances regarding molecular mechanisms and pathophysiological aspects of drug receptors in cell systems and animal models. The specific aims of these meetings will be to convene 50 and ~200 participants at the GRS and GRC, respectively; it is anticipated 9 will be discussion leaders and ~38 will be speakers. The focus of this GRS and GRC will be on G-protein-coupled receptors (GPCRs)--their structure, mechanisms of action, regulation and roles in various physiological and pathophysiological states highlighting roles in addiction. The two-day GRS program, directed at students and post-doctoral fellows, will precede the GRC, and will have a keynote address, two oral sessions and two poster sessions. The main GRC program will have a keynote address session to open the meeting, 7 scientific sessions and a closing plenary session that will focus on the topics indicated above. In addition to the oral presentations, ample opportunities for poster presentations will be provided; each participant who is not a speaker will be encouraged to present a poster. The significance of this application is that this GRS/GRC provides a unique opportunity for a broad range of scientists to synergize and enhance the pace of research on topics of major importance to both basic and clinical science. The health relatedness of this application and meeting is that GPCRs are the largest receptor family in the human genome and the most widely used targets for currently available drugs. Moreover, GPCRs play critical roles in aspects of pathogenesis and therapy of a large number of clinical disorders, including drug abuse and neuropsychiatric conditions. The anticipated outcome of this conference will be enhanced progress in those and other settings in which GPCRs and GPCR signaling have been implicated as important to physiology and pathophysiology.